- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03167216
Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction
Study Overview
Status
Intervention / Treatment
Detailed Description
Chronic pelvic pain is a hallmark of patients with CPPS, a non-bacterial category of prostatitis that is a significant source of morbidity in men. The cause of CPPS is unknown and there is a lack of biomarkers for diagnosis of this syndrome. Research in animal models of CP/CPPS have pointed to a role for mast cells and their degranulation constituents including mast cell tryptase in the development of pelvic pain and lower urinary tract symptoms. This study aims to evaluate the ability of FDA approved and marketed drugs to inhibit the release of mast cell tryptase and to ameliorate symptoms in patients with CP/CPPS.
This is an open label study to evaluate the efficacy of Cromolyn Sodium Oral Solution and Cetirizine hydrochloride (tablet) in men with CP/CPPS to reduce mast cell tryptase levels in expressed prostatic fluids and to show improvement in symptoms of CP/CPPS. There is no control group for the study. The difference between pre- and post-treatment levels across individuals will be assessed.
The study will consist of 3 periods: the Screening Period (Days -7 to -1), the Treatment Period (Days 1 to 21), and the Follow-up Period (7 days) after the last dose at Day 21.
During screening, subjects will be admitted to the clinic, undergo specimen (Expressed prostatic secretions (EPS), urine and blood) collection and recording of their baseline questionnaire responses Subjects will provide a basic health history, including current general health, adverse events, medications or treatments within the past 5 years. A physical examination including vital heart rate, breathing rate, blood pressure, temperature, height, weight and body mass will be taken. Subsequently, EPS from eligible subjects will be collected by the clinical team and assayed for the levels of mast cell tryptase within 24 hours of sample collection at the screening visit. 20 subjects with elevated mast cell tryptase will be identified and will be eligible for receiving the study medication from the Investigational pharmacy at Northwestern University.
Eligible subjects will be required to take medication for days 1-21 (Week 1-3), record their symptom scores weekly using the NIH-CPSI, and record all safety related symptoms.
Subjects will return to the clinic after the completion of three weeks of treatment. Expressed prostatic secretions (EPS), blood as well as a voided bladder 1, 2 and 3 (VB1-3) urine specimens will be collected as at baseline and after the last dose at day 21 for evaluating mast cell tryptase levels. A review subject's general health, adverse events, and any medications that have changed since the last visit will be collected. Vital signs (heart rate, breathing rate, blood pressure, temperature, weight and BMI will be collected.
Treated subjects will be contacted by phone 7 days after treatment by the study coordinator to follow up on any study related adverse effects or changes in symptoms.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Medical Faculty Foundation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male ages 21-80 years old
- Diagnosed with Category III Chronic Pelvic Pain Syndrome
- Patients reporting pain or discomfort in any of the 8 domains of the NIH_ Chronic Prostatitis Symptom Index (NIH-CPSI).
- CP/CPPS symptoms must have been present for the majority of the time during any 3 months in the previous 6 months.
- Mast cell tryptase levels in EPS above a control threshold of 25ng/ml based on healthy men.
Exclusion Criteria:
- Females
- Males <21 and >80 years old
- Patients with a known hypersensitivity to cromolyn sodium or cetirizine hydrochloride
- Patients with impaired renal or hepatic function.
- Mast cell tryptase levels in EPS equal to or below a control threshold of 25ng/ml based on healthy men.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment arm
Treated arm with cromolyn sodium and cetirizine hydrochloride
|
Mast cell stabilizer
Other Names:
Histamine receptor antagonist
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mast cell tryptase levels in expressed prostatic secretions
Time Frame: 3 weeks
|
Changes in Mast cell tryptase at the end of treatment compared to levels observed before administration of the study drug.
|
3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NIH-CPSI score
Time Frame: 3 weeks
|
Change in pelvic pain, urinary symptoms and quality of life after treatment
|
3 weeks
|
AUA-SI score
Time Frame: 3 weeks
|
Change in symptoms of lower urinary tract dysfunction after treatment
|
3 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Praveen Thumbikat, PhD, Northwestern University
Publications and helpful links
General Publications
- Done JD, Rudick CN, Quick ML, Schaeffer AJ, Thumbikat P. Role of mast cells in male chronic pelvic pain. J Urol. 2012 Apr;187(4):1473-82. doi: 10.1016/j.juro.2011.11.116. Epub 2012 Feb 17.
- Murphy SF, Schaeffer AJ, Thumbikat P. Immune mediators of chronic pelvic pain syndrome. Nat Rev Urol. 2014 May;11(5):259-69. doi: 10.1038/nrurol.2014.63. Epub 2014 Apr 1.
- Roman K, Done JD, Schaeffer AJ, Murphy SF, Thumbikat P. Tryptase-PAR2 axis in experimental autoimmune prostatitis, a model for chronic pelvic pain syndrome. Pain. 2014 Jul;155(7):1328-1338. doi: 10.1016/j.pain.2014.04.009. Epub 2014 Apr 13.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Prostatic Diseases
- Pelvic Pain
- Prostatitis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Inflammatory Agents
- Immunologic Factors
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Histamine H1 Antagonists, Non-Sedating
- Mast Cell Stabilizers
- Cetirizine
- Cromolyn Sodium
Other Study ID Numbers
- STU00202831
- 2R01DK083609-06A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Prostatitis With Chronic Pelvic Pain Syndrome
-
National Institute of Diabetes and Digestive and...CompletedChronic Prostatitis With Chronic Pelvic Pain Syndrome
-
Adrian GasparCompletedChronic Prostatitis With Chronic Pelvic Pain Syndrome | ProstatodyniaArgentina
-
Shanghai University of Traditional Chinese MedicineHuashan HospitalActive, not recruitingChronic Prostatitis With Chronic Pelvic Pain SyndromeChina
-
The Krongrad InstituteUnknownProstatitis | Chronic Prostatitis With Chronic Pelvic Pain SyndromeUnited States
-
PfizerCompletedChronic Prostatitis With Chronic Pelvic Pain SyndromeUnited States, Canada, France, Sweden, Switzerland
-
Region StockholmKarolinska InstitutetRecruitingChronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Prostatitis | Chronic Pelvic Pain Syndrome | Pelvic Floor; RelaxationSweden
-
Northwestern UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedProstatitis | Chronic Prostatitis With Chronic Pelvic Pain SyndromeUnited States
-
Beth Israel Deaconess Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedCystitis, Interstitial | Painful Bladder Syndrome | Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Bacterial Prostatitis | Asymptomatic Inflammatory ProstatitisUnited States
-
Guang'anmen Hospital of China Academy of Chinese...CompletedChronic Prostatitis With Chronic Pelvic Pain SyndromeChina
-
Kenneth Peters, MDCelgene CorporationCompletedProstatitis | Chronic Prostatitis With Chronic Pelvic Pain SyndromeUnited States
Clinical Trials on Cromolyn Sodium
-
AZTherapies, Inc.TerminatedAmyotrophic Lateral SclerosisUnited States
-
AZTherapies, Inc.WithdrawnIschemic Stroke | Post-stroke Cognitive Impairment
-
AZTherapies, Inc.CompletedAlzheimer Disease | Healthy VolunteersUnited States
-
Shiraz University of Medical SciencesCompletedEnd Stage Renal Disease | PruritusIran, Islamic Republic of
-
University of TennesseeCompletedEosinophilic EsophagitisUnited States
-
Wolfson Medical CenterUnknown
-
Universitaire Ziekenhuizen KU LeuvenJessa Hospital; Algemeen Ziekenhuis Maria MiddelaresTerminatedExercise-Induced BronchoconstrictionBelgium
-
University of California, San DiegoCompletedPapulopustular RosaceaUnited States